# The role of Tumor associated macrophages in glioblastoma

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $498,283

## Abstract

Project Summary (Abstract)
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The infiltrative nature of tumor
cells makes surgical resection incomplete. Furthermore, recurrence is inevitable despite radiation and
temozolomide treatment and patients die within 15 months following diagnosis. GBM are divided into several
molecular subtypes based on distinct gene expression profiles, including proneural (PN), mesenchymal (MES),
classical (CL). One important reason that current anti-neoplastic therapies fail to provide a durable response in
GBM is the adaptive nature of the tumor microenvironment. The most abundant non-neoplastic cell population
in the GBM microenvironment is tumor-associated macrophages (TAMs). Of the GBM subtypes, MES
expresses the highest levels of TAM-associated genes. Our analysis of TAM numbers revealed that MES GBM
also has the highest number of TAMs compared to the other subtypes. When we correlated the high and low
expression levels of TAM-associated genes with patient survival in a subtype-specific manner, only PN GBM
patients showed a correlation of high expression: short survival and low expression: long survival. PN GBM is
also known to be the most resistant to anti-neoplastic cell-specific targeted therapies. To examine TAM-GBM
cell interactions, we used genetically engineered immunocompetent mouse models of PDGFB- and NF-1 loss-
driven GBM and showed that tumor cells induce TAMs to produce the key pro-inflammatory cytokine IL-1β.
TAMs release IL-1β, which binds to the receptor IL-1R1 on tumor cells and leads to activation of IL-1β
signaling in PDGFB-driven GBM cells, which leads to i) increased stemness and growth, and ii) increased
expression of the monocyte chemoattractant protein (MCP) network (CCL2, CCL7, CCL8, CCL12) in PDGFB-
driven GBM cells. Our data showed that loss of IL-1β from the microenvironment resulted in a significant
decrease in PDGFB-driven GBM formation and growth compared to wild-type mice in vivo. Based on our data,
we hypothesize that TAM interaction with GBM cells is cell type- and subtype-specific and that they have
different functions in PN and MES GBM subtypes. In this application, we will determine the detailed
mechanism by which PN and MES GBM cells recruit and alter the function of macrophages to create
specialized TAMs (Aim 1). To determine the mechanism of IL-1β signaling, the MCP network, and their
downstream targets in PDGFB- and NF1 loss-driven GBM using genetically engineered mouse models
and human GSC-derived tumors in vivo. Determine the mechanism by which TAMs and IL-1β support
the creation and maintenance of the perivascular niche, which provides the proper microenvironment
for glioma stem cells – the treatment-resistant population of glioma (Aim 3). The proposed studies will
provide new mechanistic insights into fundamental cellular and molecular biological processes related to TAM–
tumor cell interaction in vivo, and will allow for identification of novel...

## Key facts

- **NIH application ID:** 10001027
- **Project number:** 5R01NS100864-05
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Dolores Hambardzumyan
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $498,283
- **Award type:** 5
- **Project period:** 2020-04-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001027

## Citation

> US National Institutes of Health, RePORTER application 10001027, The role of Tumor associated macrophages in glioblastoma (5R01NS100864-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10001027. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
